Collaboration Paves Way for Manufacturers to Find Logistics Solutions for Patients
Research Triangle Park, NC, November 20, 2018 – Marken announced a new collaboration with RareChannels, a global web-based reference which allows manufacturers of rare disease therapies and their affiliates to find customized logistic solutions.
According to the National Institutes of Health (NIH), 7,000 different rare diseases, sometimes referred to as ‘orphan’ diseases, affect more than 300 million people worldwide. Important scientific research has led to the development of new diagnostic and therapeutic procedures to treat these diseases. Given the number of people affected and their geographic distribution, Marken has agreed to collaborate with RareChannels which will make it easier for manufacturers to find optimal ways to deliver.
Marken has the capability to deliver any drug product, vaccine or medical device to patients anywhere in the world, regardless of complexity. Nearly half of all orphan drugs are biologically-derived and must be handled carefully with appropriate temperature controls and GPS tracking in order to assure quality of delivery. Marken understands the pharmaceutical industry’s increased focus on rare disease treatments and the need to reach a growing number of patients in remote locations. Marken has developed a specialized network, which allows the free flow of complex materials to and from any country in the world. It is a natural fit for Marken and RareChannels to work together, making it easier for breakthrough new treatments to find their patients, wherever they may be.
Wes Wheeler, Marken’s Chief Executive Officer, commented, “We are proud to offer our services to the pharmaceutical companies dedicated to finding solutions and treatments for rare diseases. Marken’s extensive network is well-positioned to provide time and temperature sensitive services, with end-to-end visibility, to the pharmaceutical industry. We look forward to working with RareChannels on the important challenges they face in the future.”
Carol Dickerson, Founder & CEO of RareChannels, stated, “When managing the nuances within specialty distribution and market access for a rare manufacturer, I was often frustrated with the accessibility to real-world experienced, content-expert specialists for the customized solutions we needed. Our issues were not those of large mainstream pharma, and the size of my organization’s needs, and budget, also did not suit the cookie-cutter solution-models that existed. I then created this concept solely to bring cures to the globe faster, cheaper, better, by building a multilingual, web-based, category or term-searchable resource to directly find niche-experts in rare. Marken’s undeniable global presence, and intense focus on specializing their many deliverables for these new therapies, makes them a perfect Partner in Rare. RareChannels is very proud and excited to have them on board.”
Marken is a wholly owned subsidiary of UPS. Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient and Home Health care services, biological sample shipments and offers a state-of-the-art GMP-compliant depot network and logistic hubs in 49 locations worldwide for clinical trial material storage and distribution. Marken’s more than 900 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 150 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.
CONTACT: Christine Noble, firstname.lastname@example.org, +1 919 474 6890, www.marken.comBack to Index